DBV Technologies Investor Relations Material
Latest events
Status Update
DBV Technologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from DBV Technologies S.A.
Access all reports
DBV Technologies S.A. is a French biopharmaceutical company focused on developing therapies for food allergies using its proprietary epicutaneous immunotherapy (EPIT) technology platform. The company's lead product candidate is designed to treat peanut allergies by delivering allergens through the skin to desensitize patients while minimizing the risk of severe allergic reactions. DBV's non-invasive approach aims to provide safe and effective treatments for patients with food allergies, addressing a significant unmet need in allergy management. The company is headquartered in Montrouge, France, and its shares are listed on Euronext Paris and the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
DBV
Country
🇫🇷 France